Monte Rosa Therapeutics, Inc. announced that Owen Wallace, Ph.D., the Company?s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.2 USD | -0.38% | +7.22% | -7.96% |
May. 16 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
May. 16 | Monte Rosa Therapeutics Prices $100 Million Public Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.96% | 318M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board